Quest Diagnostics (NYSE:DGX) PT Raised to $168.00 at Barclays

Quest Diagnostics (NYSE:DGX) had its target price lifted by equities researchers at Barclays from $154.00 to $168.00 in a research note issued on Wednesday, Benzinga reports. The brokerage presently has an “equal weight” rating on the medical research company’s stock. Barclays‘s target price would suggest a potential upside of 6.33% from the stock’s current price.

A number of other research firms also recently commented on DGX. StockNews.com raised shares of Quest Diagnostics from a “hold” rating to a “buy” rating in a research report on Tuesday, October 15th. Piper Sandler boosted their price objective on shares of Quest Diagnostics from $145.00 to $150.00 and gave the company a “neutral” rating in a report on Monday, July 29th. Evercore ISI assumed coverage on shares of Quest Diagnostics in a research report on Wednesday, August 28th. They set an “in-line” rating and a $165.00 price target for the company. Truist Financial boosted their price objective on Quest Diagnostics from $158.00 to $165.00 and gave the company a “hold” rating in a report on Monday, October 7th. Finally, Citigroup raised their price target on shares of Quest Diagnostics from $165.00 to $185.00 and gave the company a “buy” rating in a research report on Wednesday. Nine equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Quest Diagnostics has a consensus rating of “Hold” and a consensus price target of $163.33.

Quest Diagnostics Trading Up 0.6 %

Shares of DGX stock opened at $158.00 on Wednesday. The stock’s 50-day moving average price is $153.05 and its 200-day moving average price is $144.57. Quest Diagnostics has a 12-month low of $121.60 and a 12-month high of $160.95. The company has a current ratio of 1.00, a quick ratio of 0.91 and a debt-to-equity ratio of 0.57. The stock has a market capitalization of $17.55 billion, a price-to-earnings ratio of 21.27, a price-to-earnings-growth ratio of 2.45 and a beta of 0.89.

Quest Diagnostics (NYSE:DGX) last posted its quarterly earnings data on Tuesday, October 22nd. The medical research company reported $2.30 earnings per share for the quarter, beating analysts’ consensus estimates of $2.26 by $0.04. Quest Diagnostics had a net margin of 8.99% and a return on equity of 15.35%. The business had revenue of $2.49 billion for the quarter, compared to analysts’ expectations of $2.43 billion. During the same quarter in the previous year, the business posted $2.22 earnings per share. The business’s revenue was up 8.5% compared to the same quarter last year. Equities research analysts predict that Quest Diagnostics will post 8.89 EPS for the current fiscal year.

Insider Activity at Quest Diagnostics

In other news, SVP Karthik Kuppusamy sold 1,990 shares of the business’s stock in a transaction that occurred on Wednesday, August 28th. The shares were sold at an average price of $153.26, for a total transaction of $304,987.40. Following the completion of the sale, the senior vice president now owns 11,459 shares in the company, valued at approximately $1,756,206.34. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 0.79% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Quest Diagnostics

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Legacy Financial Advisors Inc. raised its position in Quest Diagnostics by 1.6% in the 2nd quarter. Legacy Financial Advisors Inc. now owns 4,697 shares of the medical research company’s stock valued at $643,000 after purchasing an additional 72 shares during the last quarter. New England Capital Financial Advisors LLC lifted its position in Quest Diagnostics by 24.7% during the 1st quarter. New England Capital Financial Advisors LLC now owns 389 shares of the medical research company’s stock worth $52,000 after acquiring an additional 77 shares during the period. Meeder Advisory Services Inc. grew its stake in shares of Quest Diagnostics by 4.9% in the 2nd quarter. Meeder Advisory Services Inc. now owns 1,795 shares of the medical research company’s stock valued at $246,000 after purchasing an additional 84 shares during the last quarter. Keudell Morrison Wealth Management increased its holdings in shares of Quest Diagnostics by 3.8% in the first quarter. Keudell Morrison Wealth Management now owns 2,312 shares of the medical research company’s stock valued at $308,000 after purchasing an additional 85 shares during the period. Finally, Arjuna Capital raised its stake in shares of Quest Diagnostics by 5.2% during the first quarter. Arjuna Capital now owns 1,770 shares of the medical research company’s stock worth $236,000 after purchasing an additional 88 shares during the last quarter. 88.06% of the stock is owned by hedge funds and other institutional investors.

Quest Diagnostics Company Profile

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.